In a letter dated October 7, the Drugs Controller General of India (DCGI) Dr Rajeev Singh Raghuvanshi emphasised the "critical importance of testing new materials, including the excipients, before their use in the manufacturing of pharmaceutical formulations."
The Drugs Controller General of India (DCGI) has reduced the time required for blood bank licensing from a year to a maximum of four months by transitioning the entire process to a digital platform.
Drugs Controller General of India (DCGI) Dr Rajeev Raghuvanshi, has said that 11 countries in the world have recognised Indian pharmacopoeia as their standard.
As per senior official sources, the DCGI is actively taking action against manufacturing companies producing drugs that do not meet the required standards of quality (NSQ). This proactive approach aims to protect public health and maintain trust in the healthcare system.
The Drugs Controller General of India (DCGI) on Wednesday suspended the product PresVu produced by Entod Pharmaceuticals after the company failed to respond to the queries on the product for which the DGCI says no approval was granted.
Union Health Minister Mansukh Mandaviya has directed the Drugs Controller General of India (DCGI) to take stringent actions against those pharmaceutical manufacturing companies that make spurious drugs.
The Government of India has cancelled the licenses of 18 pharma companies for manufacturing spurious medicines following an inspection by the Drugs Controller General of India (DCGI) on 76 companies across 20 states, sources said on Thursday.
The Union Ministry of Health is mulling shutting down digital pharmacies due to some concerns like misuse of data, Antimicrobial Resistance (AMR) and predatory pricing of medicines. In the latest development in this regard, FICCI has written a letter to the Drugs Controller General of Ind
The Union Public Service Commission (UPSC) has recommended the name of Dr Rajeev Singh Raghuvanshi as the new Drugs Controller General of India (DCGI).
The Central drug regulatory authority Drugs Controller General of India (DCGI) has recommended market authorisation for Serum Institute of India's Covid vaccine Covovax as a heterologous booster dose for those who have already taken two doses of Covishield or Covaxin.
The Drugs Controller General of India (DCGI) has given approval to intranasal "Five Arms" booster dose for restricted use for COVID-19 patients, it is learnt.